The Food and Drug Administration (FDA) is offering a funding opportunity for applied regulatory science research aimed at evaluating the cardiotoxicity of oncology therapeutics through the U01 Research Project Cooperative Agreements. This initiative seeks to enhance the detection, monitoring, and management of cardiovascular toxicities associated with cancer treatments, focusing on developing standardized definitions, improving monitoring plans, and creating predictive models that consider patient risk factors. With a total funding availability of up to $1.5 million for Fiscal Year 2025, the FDA anticipates awarding 1-3 grants over a maximum three-year project period, with applications due by August 8, 2025. Interested applicants can reach out to Patrick Johnson at patrick.johnson@fda.hhs.gov for further information and are encouraged to review the detailed announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-015.html.